Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
EyePoint Pharmaceuticals, Inc. EYPT
$5.81
-$0.52 (-8.90%)
На 18:01, 12 мая 2023
+330.29%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
219189141.00000000
-
week52high
11.44
-
week52low
2.19
-
Revenue
41404000
-
P/E TTM
-2
-
Beta
1.09065700
-
EPS
-3.26000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 12:30
Описание компании
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 04 авг 2022 г. |
| Chardan Capital | Buy | 07 июл 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 06 мая 2021 г. |
| Cantor Fitzgerald | Overweight | 28 янв 2021 г. | |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lurker Nancy | A | 450800 | 450800 | 06 янв 2023 г. |
| Duker Jay S. | A | 124755 | 124755 | 06 янв 2023 г. |
| Paggiarino Dario A. | A | 91655 | 91655 | 06 янв 2023 г. |
| Pine Michael Craig | A | 91655 | 91655 | 06 янв 2023 г. |
| Jones David Scott | A | 91655 | 91655 | 06 янв 2023 г. |
| Elston George | A | 91655 | 91655 | 06 янв 2023 г. |
| Duker Jay S. | D | 0 | 15258 | 01 ноя 2022 г. |
| Duker Jay S. | D | 21402 | 4479 | 01 ноя 2022 г. |
| Duker Jay S. | A | 25881 | 15258 | 01 ноя 2022 г. |
| Duker Jay S. | A | 65300 | 65300 | 07 сент 2022 г. |
Новостная лента
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 23:48
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Yatin Suneja - Guggenheim Tyler Van Buren - Cowen Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright Julian Harrison - BTIG Operator Good morning.
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?
Zacks Investment Research
20 апр 2023 г. в 05:20
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewsWire
27 февр 2023 г. в 08:00
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023
GlobeNewsWire
23 февр 2023 г. в 07:00
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
PennyStocks
14 ноя 2022 г. в 13:33
Analysts say these are penny stocks to buy. Do you agree?